Ask me later

Ask me later

How likely are you to recommend Redeye to a friend or colleague?

1

2

3

4

5

6

7

8

9

10

Not likely

Very likely

Not likely

1

2

3

4

5

6

7

8

9

10

Very likely

Message received

Thanks again for rating us!

2cureX Q4 2022: An efficient year

2023-02-23

14:11

Redeye comments on 2cureX’s Q4’22 report. The company summarizes the past year and highlights its strong enrollment for the IGNITE program. Furthermore, 2cureX explains the processes of how new medical technologies become mainstream.

EL

Ethel Luvall

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers